Glenmark Pharmaceuticals shares gained 2 per cent in afternoon trade on Tuesday after the company received a surprise approval from US FDA for Ezetimibe, the generic version of Merck-Schering Plough's cholesterol lowering drug 'Zetia'.According to market analysts, the drug has US sales of $1.8 billion. Ezetimibe may generate $250 million in cash flows for Glenmark during the exclusivity period.At 2.35 pm, shares of the drug maker were trading at Rs 991.60, up 1.93 per cent against their previous close.CLSA has set a target price of Rs 1,060 for the scrip. According to the investment firm, the pharma major is at the cusp of a revival with pick-up in US approvals.For the year ended March 2015, Glenmark Pharmaceuticals registered consolidated net profit of Rs 475.31 crore, down 12.35 per cent against Rs 542.28 crore last year.
Disqus for www.money99.in
Tuesday 30 June 2015
Glenmark Pharmaceuticals shares gained 2 per cent update for 30 June 2015
Posted By:
Money99
- June 30, 2015
Subscribe to:
Post Comments (Atom)
Dear Friends,
Sorry to say that you are suffered for the chart initially available, now they are restored and you can very well see the chart on money99.org similar to money99.in.
And all of you are intimated that we are going to develop more and more in money99.org to facilitate your dreamy demands.
Disqus for www.money99.in
Sponsor
Live Ami Charts
Demo chart
MCX Live chart
NSE Future Live chart
Nifty Option Live chart
FnO List of Equity Live chart
OTHER IMPORTANT LINKS
- SGX Nifty
- NSE StockFut. Live Chart
- MCX Live excel - Camarilla
- Ladder system for Crude oil
- Nifty 50 Live Excel Sheet
- Volatility tips
- Advanced Camarilla Live Excel
- Fibonacci Calculator
- Gold Price In India
- NSE FnO Lot Size
- Recent Dividends
- India Financial Data
- Commodity - 5 Basic tips
- Comex Future Price
- World Economic Calender
- Result Calendar
- NSE Bulk Deal
- FII & DII Activity
- ADV/DEC Sector Wise
- Forex Tools
- Advanced EOD chart
Alexa
Latest Post
Popular Posts
Labels
© Copyright 2015 Money99. Designed by Parag Patil
0 comentários:
Post a Comment